Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
efineptakin alfa + pembrolizumab + cyclophosphamide
- Development stage
- Phase 2
- Lead developer
- NeoImmuneTech
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral, Subcutaneous
01
Overview
A combination therapy consisting of **efineptakin alfa** (an IL-7 cytokine-based immunotherapy), **pembrolizumab** (an anti–PD-1 monoclonal antibody), and **cyclophosphamide** (an alkylating chemotherapeutic agent). **Pembrolizumab** restores anticancer immune function by inhibiting the PD-1 receptor on T-cells, **cyclophosphamide** suppresses regulatory T cells and has direct cytotoxic anticancer effects, and **efineptakin alfa** is designed to stimulate T-cell proliferation and function. This triple therapy is under clinical investigation for cancer immunotherapy, particularly in solid tumors such as ovarian cancer and advanced malignancies.
- Other names
- MSD 3475 (for pembrolizumab)NSC 26271 (for cyclophosphamide)
02
Targets
DNAIL7R (Interleukin-7 Receptor)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on efineptakin alfa + pembrolizumab + cyclophosphamide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on efineptakin alfa + pembrolizumab + cyclophosphamide.